BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 71
- Registration Number
- NCT06568458
- Locations
- 🇺🇸
Local Institution - 0001, Lenexa, Kansas, United States
Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 112
- Registration Number
- NCT06565975
- Locations
- 🇫🇷
Kappa Sante, Paris, France
Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 52
- Registration Number
- NCT06566768
- Locations
- 🇬🇧
Local Institution - 0002, Nottingham, Nottinghamshire, United Kingdom
🇬🇧Quotient Sciences, Nottingham, Nottinghamshire, United Kingdom
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1000
- Registration Number
- NCT06561386
- Locations
- 🇮🇹
Local Institution - 0222, Ravenna, Italy
🇺🇸Local Institution - 0368, Tucson, Arizona, United States
🇺🇸Local Institution - 0112, Los Angeles, California, United States
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 118
- Registration Number
- NCT06551129
- Locations
- 🇺🇸
Analysis Group Inc., Boston, Massachusetts, United States
A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 685
- Registration Number
- NCT06549608
- Locations
- 🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 134
- Registration Number
- NCT06544655
- Locations
- 🇦🇺
St Vincent's Hospital, Darlinghurst, New South Wales, Australia
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸Local Institution - 0003, Tucson, Arizona, United States
A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 150
- Registration Number
- NCT06512337
- Locations
- 🇨🇳
Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China
Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France
- Conditions
- Esophageal Adenocarcinoma (EAC)Gastro-esophageal Junction AdenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 500
- Registration Number
- NCT06504615
- Locations
- 🇫🇷
KAPPA SANTE Institution, Paris, France
🇫🇷Kappa Santé, Paris, France
Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer
- Conditions
- Esophageal CancerGastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 115
- Registration Number
- NCT06499298
- Locations
- 🇨🇳
Local Institution - 0001, Shanghai, China